A New Horizon in Treating Difficult-to-Treat Diseases by Overcoming the Blood-Brain Barrier

Central nervous system lymphoma (CNSL) is a rare and aggressive type of non-Hodgkin lymphoma that occurs in the brain and spinal cord. It is a rare disease with a very poor prognosis. The current standard of care, high-dose methotrexate-based chemotherapy, has limitations in completely eradicating tumor cells within the brain parenchyma due to its inability to fully penetrate the blood-brain barrier. In particular, patients with relapsed/refractory disease after first-line treatment have a very short life expectancy, highlighting the significant unmet medical needs. To address this, Shanghai Yake Biotechnology has developed a next-generation immunotherapy that bypasses the blood-brain barrier to directly target tumors.

Blocking the Source of Tumor Immune Evasion Through Triple-Target Design

The treatment being evaluated in this Phase 1 clinical trial is an autologous CD19-CD20-NKG2D triple-targeted chimeric antigen receptor T-cell (CAR-T) therapy, created by genetically modifying the patient's own T cells. Existing single-target CAR-T therapies have a chronic weakness in that cancer cells evade the immune system by reducing the expression of specific antigens, leading to relapse. Yake Biotechnology designed the therapy to target both CD19 and CD20, B-cell surface antigens, simultaneously to prevent resistance due to antigen loss. In addition, it incorporates the NKG2D receptor, which detects ligands exposed on the surface of tumor cells when they are stressed, to further enhance the cytotoxic effect and completely block the dual evasion pathway.

Beijing Clinical Trial Commences to Test Safety and Efficacy

The Phase 1 clinical trial to evaluate the safety and initial efficacy of this innovative triple-targeted therapy began in April 2026 at Beijing Boren Hospital in China, with patient enrollment. The primary endpoint of this study is the incidence of treatment-emergent adverse events and the objective response rate, focusing on demonstrating both safety and efficacy. A key to commercialization will be whether the CAR-T cells can safely penetrate the cerebrospinal fluid and brain tissue to eliminate tumors while controlling the potentially fatal immune effector cell-associated neurotoxicity syndrome. The clinical research team plans to manage patient risk and induce immune cell activation through a precise dose escalation design.

Accelerating Global Competition for Market Leadership in an Untapped Market

The CNS lymphoma market is currently an untapped market dominated by large multinational pharmaceutical companies, with Gilead Sciences' Yescarta leading the way, having initiated a clinical trial in 2026 to expand its indications by relaxing the criteria. The global CNS lymphoma market is estimated to grow steadily at approximately 4-7% per year from approximately $1.4 billion in 2022 to exceed $2.5 billion by 2032, making it an attractive market. Yake Biotechnology aims to establish a unique position in the market by demonstrating superior efficacy compared to existing single-target products from large pharmaceutical companies through its differentiated triple-target technology, despite being a late entrant. This clinical trial is expected to be a major milestone in the global bio-industry's expansion of cell therapy into solid tumors and CNS diseases.